Objective. The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial.
Introduction
Both biologic agents and conventional DMARDs combined with MTX are effective treatments for patients with active RA despite MTX therapy. If MTX is only used orally at doses up to 20 mg/week, 30% of RA patients will reach low disease activity; therefore, 70% of patients will need additional medications added to their MTX. The Rheumatoid Arthritis Comparison of Active Therapies Trial (RACAT) [1] demonstrated that triple therapy (T: SSZ and HCQ added to MTX) was non-inferior to etanercept added to MTX (E) in patients who had active disease despite MTX. Other recent trials also have shown that the effectiveness of triple therapy is similar to that of TNF inhibition in this patient population [14] . Obviously, the economic implications of which treatment to start first is significant, but safety issues should also be an important consideration for clinicians. In the RACAT, similar low rates of various adverse events (AEs) were reported for both therapies with the exception of infectious and gastrointestinal (GI) events, the two most common AEs. This study examines the difference in infectious and GI AEs between T and E therapies, taking into account possible confounders. Comparison of observed infectious and GI AEs between the two therapies could be a crucial factor to help clinicians make better decisions when prescribing these medications, especially given that the two therapies were found to have similar efficacy in RACAT and other trials.
Methods

Trial design and data
The design of the trial is reported in detail elsewhere [1] . Briefly, the trial protocol is as follows. In the 48-week double-blind trial, 353 patients with active RA despite MTX (mean dose 19.6 mg/week) were randomized to receive either SSZ and HCQ added to MTX (T therapy) or etanercept added to MTX (E therapy). Patients without significant improvement in RA disease (DAS28-ESR improvement of 51.2) at 24 weeks of the trial were switched in a blinded fashion to the other therapy (either from T to E therapy or from E to T therapy). After 48 weeks, there were 134 patients who had received T therapy only, 131 patients who had received E therapy only and 88 patients who had switched treatment therapies (44 patients switched from T to E, and 44 patients switched E to T). Importantly, both treatment groups tolerated the therapy well, with 88% of those in the T group and 89% of those in the E group completing the trial per protocol. Twenty-one patients (12%) in the T group and 20 patients (11%) in the E group did not complete per protocol. Reasons for dropout were similar and equally distributed in both treatment groups, with the most common reasons being unwillingness to complete follow-up visits without receiving drug therapy (41%) and patients withdrawing consent (54%). Other reasons included loss to follow-up (one patient in the T group vs four patients in the E group), one death (E group) and one patient who moved out of the area (E group). Numbers of infectious non-serious AEs (NAEs), GI NAEs and GI SAEs between completers and dropouts were similar. However, the dropouts were more likely to have a higher number of infectious SAEs than the completers (9.8 vs 3.2%, P = 0.04).
AEs in RACAT were reported and recorded every 6 weeks during the intervention and also for 4 weeks after the intervention period [1] . The events were then classified, and coded by blinded reviewers. The crude rates of various types of AEs were similar in the two therapy groups except for infectious and GI AEs [1] . We therefore examine further the difference between the two therapy groups in infectious and GI AEs: infectious NAEs, infectious serious AEs (infectious SAEs), GI NAEs and GI SAEs. The covariates that consist of demographic characteristics (age, education, gender and race), BMI, duration of RA, cigarette smoking status and medical history are included in the analysis to control for their potential confounding effects on these AEs.
Statistical analyses
The characteristics of the study patients were compared among four study groups divided based on the therapies received and whether switching occurred at 24 weeks. The comparisons were conducted using analysis of variance for continuous variables and the 2 test for categorical variables.
Owing to the small number of the switcher patients and the few AEs (14.7%) that occurred among them, we analysed the data based on a patient's treatments when AEs occurred. Initially, 178 patients on T therapy and 175 patients on E therapy were included in the analyses. Thirteen switcher patients had occurrence of the same NAEs (infection or GI) both before and after they switched the treatment. To avoid including the same patient in both treatment groups and to be conservative in the analysis, we assigned the patient to the treatment group that had fewer reported events. As a result, eight switching patients were included in the T group when comparing infection rate, and five switching patients were included in the E group when comparing GI rate. We did not have to apply the same approach when analysing SAEs because none of the switcher patients had SAEs that occurred during the time around the switch.
We compared the proportion of patients with any of infectious and GI events between the two treatments (E vs T) first using the 2 test. We then compared the rate of events per person-year between two treatments. The person-years were calculated as the duration (in years) in which each participant received study treatment. We then used a generalized linear model with log link and negative binomial distribution to estimate the incidence rate ratio (IRR) of NAEs in E vs T treatments with and without adjusting for potential confounders (age, gender, race, BMI, cigarette smoking and co-morbidities). The comorbidities included myocardial infarction, cerebrovascular accident, congestive heart failure, respiratory disease, peptic ulcers, hepatitis, renal/ genito-urinary, diabetes (type 1), diabetes (type 2), musculoskeletal and psychiatric diseases. The generalized linear model was not applied to SAEs because of the small number of events.
In addition to the analysis using the method described above for handling events that occurred in switchers, we also conducted sensitivity analysis by including all events that occurred both before and after switching. The unit of analysis was the event, and one patient could have more than one record/event included in the analysis. Generalized estimating equations (GEEs) were used to account for the correlation among events that occurred in https://academic.oup.com/rheumatology the same patient. We used SAS 9.2 (SAS Institute Inc, Cary, NC, USA) for all the analyses for the study.
The trial was approved by the Institutional Review Board at the Boston Coordinating Center, VA Boston Healthcare System and at each participating site (37 sites) for human subject research. All enrolled patients signed an informed consent form that was approved by the Institutional Review Board. An external safety monitoring committee monitored the trial for safety and scientific integrity.
Results
A total of 353 patients participated in the study. The mean (S.D.) age of these patients was 57 (13) years (range 2086). Fifty-four per cent were male, and 88% were white. About one-quarter of the patients were current cigarette smokers (26%). The prevalence of patients who had at least two co-morbidities, one co-morbidity and no co-morbidity was 42, 35 and 23%, respectively. The mean (S.D.) BMI was 29.7 (6.3) kg/m 2 (range:
. Approximately three-quarters of the patients stayed on the initially assigned therapy during the 48 weeks of the trial, including 134 patients on the T therapy and 131 patients on the E therapy. Meanwhile, about one-quarter of patients switched into the other therapy at week 24 because they did not sufficiently respond to the initial therapy (their score on DAS28 did not decrease by 1.2 or more). An equal number (44) of patients required a switch of therapy from the initial T therapy to E therapy and from the initial E therapy to T therapy. The four groups of patients (T vs E) vs (switching vs no-switching) were similar in age, socio-demographics, cigarette smoking, duration of RA and co-morbidities (Table 1) .
Infectious NAEs
For both therapies, the majority of infectious AEs were non-serious, such as upper respiratory tract infection, nasopharyngitis, sinusitis, oral herpes, bronchitis, influenza, pneumonia, tooth abscess and infection, and urinary tract infection, etc. There were 130 patients (36.8% of patients) who reported at least one infectious NAE, including 75 patients out of 175 on E therapy and 55 patients out of 178 on T therapy. The proportion of patients who had infectious NAEs was higher in the E therapy group than in the T therapy group (43 vs 31%, P = 0.02). There were a total of 199 events that occurred among these 130 patients (125 in E and 74 in T). When taking into account the exposure time to the therapies, the E therapy had a significantly higher incidence rate per person-year than the T therapy (IRR = 1.66, 95% CI: 1.18, 2.23, P 4 0.01). As shown in Table 2 , the difference between the two therapies in the incidence rate remained significant after adjusting for age, gender, race, BMI, cigarette smoking and co-morbidity (IRR = 1.56, 95% CI: 1.11, 2.19, P = 0.01). Results were obtained from the sensitive analysis using the GEE approach (IRR = 1.69, 95% CI: 1.24, 2.30, P < 0.01).
Infectious SAEs
Regarding the number of patients with infectious SAEs, there were a total of 14 patients who had at least one event (4% of the study population), which included 10 patients out of 175 (5.7%) on E therapy and 4 patients out of 178 (2.2%) on T therapy at the time when the events occurred. Although patients who were currently on E therapy were more likely to have serious infectious events than patients who were on T therapy, the difference between the two groups was not statistically significant (P = 0.11). When looking at the number of infectious SAEs, the patients on E therapy had more infectious SAEs than patients on T therapy (12 on E vs 4 on T). Two out of 10 patients on E therapy had more than one infectious SAE, which yielded a total of 12 events, while each of four patients on T therapy had only one SAE, which yielded a total of four events. Figure 1 shows the 16 different infectious SAEs broken down into either E (12 events) or T therapies (four events). Infectious respiratory problems (bronchitis and pneumonia) occurred more often with E therapy compared with T therapy (seven vs two events, respectively); one patient who was on E therapy died from respiratory infection and one had severe aspergillosis requiring long-term respiratory support. Other types of infectious SAEs occurring in the E therapy group included two cases of oral/ nasopharyngeal infections and one case each of renal/ genito-urinary, soft tissue and viral infection. Besides the two pneumonia cases among the T therapy group, there was one case of Clostridium difficile colitis and one case of diverticulitis.
GI NAEs
There were 104 patients (29.5% of the study population) who had at least one GI NAE [58 patients (32.6%) on T therapy and 46 (26.3%) patients on E therapy]. The most common GI NAEs included nausea, diarrhoea, abdominal discomfort and pain, vomiting, constipation, dyspepsia and stomatitis. A total of 157 GI NAEs occurred among these 104 patients (97 in T and 60 in E). The E therapy had a much lower incidence rate than the T therapy (IRR = 0.59, 95% CI: 0.39, 0.89, P = 0.02). As shown in Table 2 , the difference remained at the same significance level after adjusting for age, gender, race, BMI, cigarette smoking and co-morbidity (IRR = 0.62, 95% CI: 0.40, 0.94, P = 0.02). Results were obtained from the sensitive analysis using the GEE approach (IRR = 0.57, 95% CI: 0.40, 0.82, P = 0.002).
GI SAEs
There were eight patients with GI SAEs (2.3% of the study population), which included four patients (2.3%) on T therapy and four patients (2.3%) on E therapy. There was no difference in GI SAEs between the two therapies (2.8% for T therapy vs 1.7% for E therapy, P = 0.48). Figure 2 indicates the number of GI SAEs in different therapies. Three events of GI haemorrhage (1.7%) occurred when patients were on E therapy. There were two cases of gastritis (1.1%), one case of a bowel obstruction (0.6%) and one case with ileus (0.6%) among patients on T therapy. Pancreatitis occurred in one patient in each group (0.6% on T vs 0.6% on E therapy).
The study dropout related to infectious AEs and GI AEs
Seventeen patients discontinued the study for different reasons. Among them, five patients discontinued the trial because of their infectious problems, four patients on E (two NAEs and two SAEs) and one on T therapy (SAE). Three patients discontinued the trial because of their GI problems, one patient on T (NAE) and two on E therapy (one SAE and one NAE). Therefore, E therapy was associated with discontinuation in six patients because of either infectious AEs or GI AEs, and T was associated with discontinuation in two patients because of either infectious AEs or GI AEs.
Discussion
The time has come when rheumatologists are being graded on the basis of the value of care they deliver. Therefore, the goal when treating patients with RA should be to maximize efficacy and minimize toxicity and cost. The RACAT and several other recent studies have shown that triple therapy and MTXanti-TNF combinations provide similar efficacy. To our knowledge, our study is the first randomized trial in RA patients with active disease despite MTX treatment that reports safety signal differences between conventional and biologic therapy. This is important information as clinicians attempt to select the therapy that will provide the greatest value for each patient. The results of the in-depth analysis reported in this paper provide evidence that E therapy increases the risk of infectious events compared with T therapy during the 48 weeks of the trial. Although no individual trial has been powered to look for safety signals in this population, our finding is consistent with the previous meta-analysis conducted by Bongartz et al. showing that patients receiving TNF inhibition have higher infectious AEs and that taking E therapy increases the rate of SAEs by about three times compared with controls [58]. Furthermore, the incidence of infectious AEs that occurred during the trial is similar to the previous studies [9] . Patients in our trial in general had more co-morbidities and therefore may have been more likely to have infectious complications. TNF inhibition is associated with increased tuberculosis reactivation, histoplasmosis, coccidioidomycosis, listeriosis and other opportunistic infections [1013] . In this trial, we did not have any tuberculosis cases or granulomatous infections, but we did have a severe near-fatal case of aspergillosis (on etanercept). Curtis et al. [14] conducted a retrospective cohort study of RA patients enrolled in a large health-care organization and found that TNF users, including patients treated with etanercept, tend to have a higher risk of hospitalization-acquired bacterial infections than MTX-only patients.
Pneumonia was the most common SAE among patients on E therapy, which may be related to the cause of one death among the patients on E therapy in this trial. Oral/ nasopharyngeal, bronchitic, renal and genito-urinary, soft tissue and viral infections were also observed in patients on E therapy. Meanwhile, infectious SAEs (including pneumonia) among patients receiving T therapy occurred less often.
Approximately 40% of the participants in this trial were enrolled from the Veterans Affairs health-care system, so this trial is the only published major trial where men outnumbered women (54% males). In general, RA is felt to be similar in males and females, but males have been reported to have more pulmonary disease and to respond to treatment better than females. In this trial, we did find a better treatment response in males, but there was no evidence of a differential response between therapies. It could be speculated that the increased proportion of males in the study would lead to greater pulmonary complications. However, there was no evidence to suggest that sex differentiated AEs overall or between the two therapies. The study used a double-blinded and randomized design, so the duration of steroid use, gender, disease activity and other covariates were roughly equally distributed in both treatment strategies.
Not surprisingly to many clinicians who have expressed concern about the GI issues with T therapy, we did find an increased incidence of GI NAEs, but this difference was small (32% on T vs 27% on E therapy) and, importantly, did not result in a differential study withdrawal rate. Furthermore, serious GI events occurred equally with each therapy (four in each group). Goffe et al. [15] reported that the SAE of GI haemorrhage can occur among people on E therapy. Importantly, the SSZ used in our study was enteric coated, and enteric coating of SSZ has been shown to improve tolerance.
As with any single study, our findings should be interpreted with some limitations in mind. Of note, this study allowed for a blinded switch to the other arm at 24 weeks if clinically indicated; therefore, attribution of any AE to a particular therapy in those patients who switched (25%) can be problematic. Among patients in the switching treatment groups, even though the AEs were recorded and assigned to the therapy at the time when the AEs occurred, there are possible carry-over effects from the previous treatment during a time window after switching therapies. However, we believe that carry-over effects are unlikely because only four (three GI NAE and one GI SAE) of these events occurred within 2 weeks after the switch. Sensitivity analyses also were conducted by including all events from switchers and assigning the treatment groups corresponding to the period when the event occurred. As such, the unit of analysis is the event. We used a GEE to account for the correlation among the repeated events that occurred in the same patient. The results also confirmed that our primary approach (using the patient as the unit of analysis) for handling events both before and after switching is more conservative, because the GEE approach produced stronger evidence than the primary approach. Therefore, we are confident in our findings of increased infectious AEs with etanercept and increased GI AEs with triple therapy.
In conclusion, the RACAT [1] demonstrated that triple therapy (T; SSZ and HCQ added to MTX) was non-inferior to etanercept and MTX (E) in patients who had active disease despite MTX. Rates of infectious NAEs were significantly increased in patients receiving E compared with T therapy, even after controlling for patient demographics and co-morbidities; GI NAEs were more frequent in T therapy. Although numbers of SAEs were small, there was a trend towards a greater number of infectious SAEs when receiving E therapy.
When RA patients have active disease despite optimal MTX, clinicians need to add additional therapy, presumably conventional combinations or a biological therapy. Although the economic advantage of T over a biological therapy is well known, the findings of differential toxicity will give clinicians additional information to make the bestvalue choice for each individual patient.
